Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00B3VWM098
| Stock Name / Fund | iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc |
| Issuer | Blackrock |
| Entity holding fund | iShares VII Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300Q7FFITMZ2PFZ28 |
| ETF Ticker | CUS1(GBX) LSE |
| ETF Ticker | CUSS(USD) LSE |
| ETF Ticker | SXRG(EUR) F |
| ETF Ticker | CSUSS.MI(EUR) CXE |
| ETF Ticker | CSUSSz(USD) CXE |
| ETF Ticker | CUSS.LS(USD) CXE |
| ETF Ticker | CSUSS(EUR) ETF Plus |
| ETF Ticker | CUS1.L(GBP) LSE |
| ETF Ticker | CUSS.L(GBP) LSE |
Holdings detail for NAMS
| Stock Name | NewAmsterdam Pharma Company N.V. Ordinary Shares |
| Ticker | NAMS(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
Show aggregate NAMS holdings
News associated with NAMS
- Biotech And Medtech Stocks Rally After-Hours Across Key Names
- (RTTNews) - On September 12, several healthcare and biotech stocks experienced a surge in after-hours trading, marked by sharp price movements across the sector. From thrombectomy devices to AI-powered diagnostics and T-cell therapies, companies including Penumbra, Check-Cap, Ada - 2025-09-15 01:33:05
- NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 9.7% on Insider Selling
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) shares were down 9.7% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $24.60 and last traded at $24.38. Approximately 255,361 shares traded hands during mid-day trading, a decline of 71% from the average daily volume […] - 2025-09-10 02:25:12
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price […] - 2025-09-02 04:26:55
- NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Wells Fargo & Company
- Research analysts at Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report issued on Monday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $45.00 price target on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 78.64% from […] - 2025-08-27 02:30:44
- Zurcher Kantonalbank Zurich Cantonalbank Grows Position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
- Zurcher Kantonalbank Zurich Cantonalbank raised its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 130.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,990 shares of the company’s stock after acquiring an additional 3,390 shares […] - 2025-08-11 04:32:58
- Arizona State Retirement System Buys Shares of 10,486 NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
- Arizona State Retirement System purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 10,486 shares of the company’s stock, valued at approximately $215,000. Several other large investors have also recently added to or reduced their stakes in the […] - 2025-07-23 04:54:51
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Buy” from Analysts
- Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a […] - 2025-07-14 05:38:50
- NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Citigroup
- Stock analysts at Citigroup started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $42.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 130.77% from the stock’s current price. Other analysts […] - 2025-06-19 02:26:48
- Cantor Fitzgerald Begins Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)
- Stock analysts at Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an “overweight” rating and a $42.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 115.27% from the company’s previous […] - 2025-06-06 04:30:47
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,288 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) by 6.0% during the fourth quarter, HoldingsChannel reports. The firm owned 253,571 shares of the company’s stock after buying an additional 14,288 shares during the period. UBS AM a distinct business unit of […] - 2025-06-02 05:32:58
- 28,517 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Bought by Lazard Asset Management LLC
- Lazard Asset Management LLC acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,517 shares of the company’s stock, valued at approximately $732,000. Other institutional investors and hedge funds have […] - 2025-05-21 05:38:58
- 2,000 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by National Bank of Canada FI
- National Bank of Canada FI purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000 shares of the company’s stock, valued at approximately $51,000. Other large investors have also recently modified […] - 2025-04-13 05:44:48
- Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33
- Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year […] - 2025-04-08 02:33:05
- Keybank National Association OH Purchases Shares of 9,983 NewAmsterdam Pharma (NASDAQ:NAMS)
- Keybank National Association OH purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,983 shares of the company’s stock, valued at approximately $257,000. Other large investors also recently bought and sold […] - 2025-03-12 05:49:05
- NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Brokerages
- NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year […] - 2025-02-19 05:06:49
iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc NAMS holdings
| Date | Number of NAMS Shares Held | Base Market Value of NAMS Shares | Local Market Value of NAMS Shares | Change in NAMS Shares Held | Change in NAMS Base Value | Current Price per NAMS Share Held | Previous Price per NAMS Share Held |
|---|
| 2025-09-26 (Friday) | 16,078 | USD 458,223 | USD 458,223 | | | | |
| 2025-09-25 (Thursday) | 16,078 | USD 422,691 | USD 422,691 | 0 | USD -7,556 | USD 26.29 | USD 26.76 |
| 2025-09-24 (Wednesday) | 16,078 | USD 430,247 | USD 430,247 | | | | |
| 2025-09-17 (Wednesday) | 15,974 | USD 391,203 | USD 391,203 | | | | |
| 2025-09-16 (Tuesday) | 15,974 | USD 391,682 | USD 391,682 | | | | |
| 2025-09-12 (Friday) | 15,870 | USD 383,895 | USD 383,895 | | | | |
| 2025-09-11 (Thursday) | 15,870 | USD 422,142 | USD 422,142 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of NAMS by Blackrock for IE00B3VWM098
Show aggregate share trades of NAMS| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2024-12-06 | BUY | 68 | | | 18.350* | | 19.78 |
| 2024-12-05 | BUY | 17 | | | 18.070* | | 20.03 |
| 2024-12-04 | BUY | 85 | | | 18.270* | | 20.32 |
| 2024-11-29 | BUY | 85 | | | 19.850* | | 20.81 |
| 2024-11-27 | BUY | 68 | | | 20.800* | | 20.84 |
| 2024-11-26 | BUY | 17 | | | 20.840* | | 0.00 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of NAMS
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 137,381 | 5,561 | 174,141 | 78.9% |
| 2025-09-18 | 234,648 | 39,983 | 330,406 | 71.0% |
| 2025-09-17 | 222,327 | 13,257 | 253,321 | 87.8% |
| 2025-09-16 | 176,647 | 0 | 242,975 | 72.7% |
| 2025-09-15 | 235,611 | 14 | 398,801 | 59.1% |
| 2025-09-12 | 421,070 | 25,427 | 640,983 | 65.7% |
| 2025-09-11 | 369,065 | 66,561 | 618,312 | 59.7% |
| 2025-09-10 | 409,300 | 65,129 | 611,115 | 67.0% |
| 2025-09-09 | 388,343 | 94,605 | 587,672 | 66.1% |
| 2025-09-08 | 685,810 | 54,545 | 1,066,204 | 64.3% |
| 2025-09-05 | 330,795 | 5,022 | 966,098 | 34.2% |
| 2025-09-04 | 199,841 | 12,222 | 294,974 | 67.7% |
| 2025-09-03 | 304,023 | 34,109 | 542,466 | 56.0% |
| 2025-09-02 | 187,216 | 0 | 238,626 | 78.5% |
| 2025-08-29 | 219,306 | 0 | 336,693 | 65.1% |
| 2025-08-28 | 158,232 | 0 | 489,348 | 32.3% |
| 2025-08-27 | 151,792 | 0 | 323,859 | 46.9% |
| 2025-08-26 | 259,952 | 25,225 | 750,177 | 34.7% |
| 2025-08-25 | 140,884 | 3,205 | 207,639 | 67.9% |
| 2025-08-22 | 173,025 | 34,454 | 279,957 | 61.8% |
| 2025-08-21 | 124,822 | 0 | 366,773 | 34.0% |
| 2025-08-20 | 117,042 | 6,425 | 177,425 | 66.0% |
| 2025-08-19 | 260,036 | 11,482 | 338,093 | 76.9% |
| 2025-08-18 | 334,044 | 34,445 | 413,302 | 80.8% |
| 2025-08-15 | 458,493 | 32,803 | 636,647 | 72.0% |
| 2025-08-14 | 232,500 | 16,048 | 280,781 | 82.8% |
| 2025-08-13 | 215,533 | 39,624 | 262,072 | 82.2% |
| 2025-08-12 | 413,931 | 10,899 | 553,320 | 74.8% |
| 2025-08-11 | 260,500 | 0 | 328,594 | 79.3% |
| 2025-08-08 | 1,083,048 | 35,405 | 1,237,405 | 87.5% |
| 2025-08-07 | 178,568 | 40 | 271,729 | 65.7% |
| 2025-08-06 | 227,638 | 197 | 467,454 | 48.7% |
| 2025-08-05 | 158,002 | 0 | 244,623 | 64.6% |
| 2025-08-04 | 79,585 | 0 | 226,857 | 35.1% |
| 2025-08-01 | 96,766 | 0 | 228,367 | 42.4% |
| 2025-07-31 | 198,698 | 0 | 281,748 | 70.5% |
| 2025-07-30 | 412,079 | 3 | 602,778 | 68.4% |
| 2025-07-29 | 184,163 | 0 | 387,947 | 47.5% |
| 2025-07-28 | 155,463 | 17 | 261,456 | 59.5% |
| 2025-07-25 | 170,477 | 7,601 | 271,749 | 62.7% |
| 2025-07-24 | 244,814 | 829 | 375,811 | 65.1% |
| 2025-07-23 | 202,603 | 0 | 385,960 | 52.5% |
| 2025-07-22 | 164,390 | 0 | 670,413 | 24.5% |
| 2025-07-21 | 180,067 | 0 | 526,444 | 34.2% |
| 2025-07-18 | 215,052 | 0 | 464,058 | 46.3% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.